Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2008-05-27
2008-05-27
Allen, Marianne P (Department: 1647)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S069100, C435S071100, C435S071300, C435S320100, C435S325000, C435S252300, C435S252330, C536S023100, C536S023700
Reexamination Certificate
active
07378257
ABSTRACT:
The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.
REFERENCES:
patent: WO 96/36366 (1996-11-01), None
patent: WO 97/36932 (1997-10-01), None
Briggs et al., “Mutations affecting the superantigen activity of staphylococcal enterotoxin B”, Immunology 1997, vol. 90, pp. 169-175.
Rosendahl et al., “A mutation of F47 to A in Staphylococcus enterotoxin A activated the T-cell receptor VB repertoire in vivo”, Infection and Immunity, Dec. 1997, vol. 65, No. 12, pp. 5118-5124.
Grossman et al., “Mutation of the disulfide loop in staphylococcal enterotoxin A”, J. Immunology, vol. 147, No. 10, pp. 3274-3281, Nov. 15, 1991.
Bavari et al., “Engineered Bacterial Superantigen Vaccines”, Vaccines 96, pp. 135-141 (1996).
Bavari et al., “Superantigen Vaccines: A Comparative Study of Genetically Attenuated Receptor-Binding Mutants of Staphylcoccal Enterotoxin A”, J. Infectious Diseases, 1996, 174:338-345.
Hurley et al., “Identification of Class II Major Histocompatibility Complex and T Cell Receptor Binding Sites in the Superantigen Toxic Shock Syndrome Toxin 1”, J. Exp. Med., vol. 181, 2229-2235, Jun. 1995.
Stiles, et al., “Toxicity of Staphylococcal Enterotoxins Potentiated by Lipopolysaccharide: Major Histocompatibility Complex Class II Molecule Dependency and Cytokine Release”, Infection and Immunity, vol. 61, No. 12, pp. 5333-5338, Dec. 1993.
Dannecker et al. (1994) Activation of human T cells by the superantigen Staphylococcus enterotoxin B: Analysis on a cellular level.Immunobiology190: 116-126.
Gonzalo et al. (1992) Expansion and clonal deletion of peripheral T cells induced by bacterial superantigen is independent of the interleukin-2 pathway.Eur. J. Immunol.22:1007-1011.
Bavari et al. (1995) Genetically attenuated bacterial superantigen vaccines.J. Cellular BiochemistrySuppl. 21A, abstract C2-204 p. 88.
Bavari et al. (1995) Staphylococcal Enterotoxin A and toxin shock syndrome toxin complete with CD4 for human major histocompatibility complex class II binding.Infection and Immunity63:423-429.
Mahana et al. (1995) A natural mutation of the amino acid residue at position 60 destroys staphylococcal enterotoxin A murine T-cell mitogenicity.Infection and Immunity63:2826-2832.
Woody et al. (1998) Differential immune responses to Staphylococcal enterotoxin B mutations in a hydrophobic loop dominating the interface with major histocompatibility complex class II receptors.J. Infectious Diseases177: 1013-1022.
Bavari, S. et al. (1996) Superantigen vaccines: A comparative study of genetically attenuated receptor-binding mutants of Staphylococcal enterotoxin A.J. Inf. Dis.174:338-345.
Ulrich, R. G. et al. (1995) Staphylococcal enterotoxins A and B share a common structural motif for binding class II major histocompatibility complex molecules.Nature Structural Biology2:554-560.
Stiles, B. G. et al. (1993) Toxicity of Staphylococcal enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex calss II molecule dependency and cytokine release.Infect. Immun.61:5333-5338.
Hurley, J. M. et al. (1995) Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxin shock syndrome toxin 1.J. Exp. Med.181:2229-2234.
Ulrich, R. G. et al. (1995) Bacterial superantigens in human disease: structure, function and diversity.Trends in Microbiology3: 463-468.
Bavari, S. et al. (1996) Engineered bacterial superantigen vaccines. InVaccines 96, Cold Spring Harbor Laboratory Press, p. 135-141.
Bavari Sina
Olson Mark A.
Ulrich Robert G.
Allen Marianne P
Arwine Elizabeth
The United States of America as represented by the Secretary of
LandOfFree
Bacterial superantigen vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bacterial superantigen vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bacterial superantigen vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2783615